Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

amulirafusp alfa (IMM0306)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

ImmuneOnco Biopharma

Drug class:

CD20 inhibitor, CD47 inhibitor

Related drugs:

‹

anti-CD47 monoclonal antibody (0)

PF-07901800 (0)

rituximab (174)

obinutuzumab (68)

epcoritamab-bysp (11)

ublituximab-xiiy (7)

rituximab-pvvr (6)

rituximab-abbs (6)

rituximab/hyaluronidase (5)

Rixathon (rituximab biosimilar) (4)

ibritumomab tiuxetan (3)

mosunetuzumab-axgb (2)

rituximab-arrx (2)

glofitamab-gxbm (1)

TQB2303 (rituximab biosimilar) (1)

odronextamab (1)

Ritucad (rituximab biosimilar) (1)

AcellBia (rituximab biosimilar) (0)

zuberitamab (0)

Avetux (rituximab biosimilar) (0)

BI 695500 (rituximab biosimilar) (0)

CIMAbior (rituximab biosimilar) (0)

DI Leu16 IL-2 (0)

GB241 (rituximab biosimilar) (0)

Halpryza (rituximab biosimilar) (0)

Hanlikon (rituximab biosimilar) (0)

Reditux (rituximab biosimilar) (0)

JHL1101 (rituximab biosimilar) (0)

Kikuzubam (rituximab biosimilar) (0)

MK-8808 (rituximab biosimilar) (0)

MabionCD20 (rituximab biosimilar) (0)

Mabtas (rituximab biosimilar) (0)

Novex (rituximab biosimilar) (0)

ocrelizumab (0)

Retuxira (rituximab biosimilar) (0)

SAIT101 (rituximab biosimilar) (0)

SIBP-02 (rituximab biosimilar) (0)

TG20 (rituximab biosimilar) (0)

ABBV-IMAB-TJC4 (2)

PF-07257876 (0)

anti-CD47 monoclonal antibody (0)

PF-07901800 (0)

›

CD20 positive	Follicular Lymphoma	CD20 positive	Follicular Lymphoma	IMM0306 Sensitive: C2 – Inclusion Criteria IMM0306 Sensitive : C2	IMM0306 Sensitive: C2 – Inclusion Criteria IMM0306 Sensitive : C2
CD20 positive	Marginal Zone Lymphoma	CD20 positive	Marginal Zone Lymphoma	IMM0306 Sensitive: C3 – Early Trials IMM0306 Sensitive : C3	IMM0306 Sensitive: C3 – Early Trials IMM0306 Sensitive : C3